Tramadol: Weak Mu Agonism, CYP2D6 Activation, Seizures and Serotonin Syndrome

Reviewed 10 November 2026 for medical education. This is not an individualized prescribing guide; refer to current local product labels and qualified clinicians.

Overview and correct chemical class

Tramadol is a synthetic cyclohexanol-derived centrally acting opioid analgesic, not a beta-substituted butyrophenone. It has weak parent-drug mu-opioid agonism and inhibits norepinephrine and serotonin reuptake. The O-desmethyltramadol (M1) metabolite has substantially higher mu-receptor affinity and contributes importantly to analgesia and respiratory risk. Tramadol is a controlled opioid in many jurisdictions and is not an inherently nonaddictive ‘non-narcotic’ agent [1,2].

Stereochemistry and pharmacodynamics

Tramadol is marketed as a racemate: the (+) enantiomer more strongly inhibits serotonin uptake and the (−) enantiomer preferentially inhibits norepinephrine uptake, while mu activity and metabolite formation also contribute. Opioid and monoaminergic mechanisms can produce analgesia but also sedation, serotonin toxicity and seizures. Contrary to older assumptions, opioid-like harms occur at therapeutic doses in susceptible patients [1].

CYP2D6 and pharmacogenetics

CYP2D6 converts tramadol to active M1; CYP3A4 and CYP2B6 participate in other metabolic pathways. Ultrarapid CYP2D6 metabolizers may develop excessive M1 exposure and potentially fatal respiratory depression, whereas poor metabolizers may have reduced opioid-mediated analgesia. CYP2D6 inhibitors (such as fluoxetine, paroxetine or bupropion) can decrease M1 while increasing parent tramadol exposure, changing both efficacy and serotonin/seizure risk [1,2].

Clinical positioning

The US ULTRAM label reserves tramadol for adults with pain severe enough to require an opioid and inadequately managed by alternatives; ordinary nonopioid and nonpharmacologic therapies are preferred when effective. Immediate-release and extended-release products have distinct indications and dosing. The medication should not be represented as preferred first-line therapy for neuropathic pain or as safe simply because it is less potent than morphine at mu receptors [2].

Boxed warnings and pediatric restrictions

US labeling contraindicates tramadol in children younger than 12 years and in patients younger than 18 years following tonsillectomy and/or adenoidectomy; use in other adolescents with breathing-risk factors is discouraged. Other boxed warnings concern addiction, respiratory depression, accidental ingestion, neonatal opioid withdrawal and interactions with sedatives. Do not prescribe tramadol during breastfeeding under US labeling due to M1 exposure risk [2].

Seizures, serotonin toxicity and other precautions

Tramadol can precipitate seizures even within recommended dosing ranges, particularly with epilepsy, overdose, antidepressants or other seizure-threshold-lowering drugs. Combined use with SSRIs, SNRIs, MAO inhibitors, linezolid or other serotonergic medicines increases serotonin syndrome risk; MAO inhibitors are contraindicated within specified washout periods. Kidney impairment can prolong exposure and requires product-specific adjustment. Provide naloxone consideration, avoid abrupt withdrawal in dependent patients and monitor sedation and respiration [1,2].

References

  1. Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
  2. US Food and Drug Administration. ULTRAM (tramadol hydrochloride) tablets: prescribing information, updated 2025–2026; CYP2D6 and pediatric contraindications. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/020281s049lbl.pdf
Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *